ID 83933
著者
イワハシ シュウイチ Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
イシバシ ヒロキ Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
ウツノミヤ トオル Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School
モリネ ユウジ Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Ochir, Lkhaguva Tovuu Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School
ハナオカ ジュン Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School
森 大樹 Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
イケモト テツヤ Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
イムラ サトル Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
島田 光生 Department of Digestive Surgery and Transplantation, Institute of Health Biosciences, the University of Tokushima Graduate School 徳島大学 教育研究者総覧 KAKEN研究者をさがす
キーワード
pancreas cancer
cholangiocarcinoma
HDAC inhibitor
valproic acid
epigenetic regulation
資料タイプ
学術雑誌論文
抄録
Background : Histone deacetylase (HDAC) is well known to be associated with
tumorigenesis through epigenetic regulation, and its inhibitors (HDACIs) induce differentiation
and apoptosis of tumor cells. We examined the therapeutic effects of valproic
acid (VPA, a HDACI) with a combination of 5-fluorouracil (5-FU) in vitro. Methods : A human
pancreas cancer cell line (SUIT-2) and a cholangiocarcinoma cell line (HuCCT1) were
used. Cell viabilities were evaluated by a cell proliferation assay. We determined the anticancer
effects of VPA combined with 5-FU in these cell lines. Results : Pancreas cancer
(SUIT-2) : No effect of 5-FU (1.0 μM) was observed, but 17% and 30% of proliferationinhibitory
effects were recognized in a dose of 2.5 or 5.0 μM, respectively. Cell viability
was only weakly reduced by VPA (0.5 mM). However, in combination of 5-FU (1.0 μM)
with VPA (0.5 mM), 19% of inhibitory effect was observed. Cholangiocarcinoma (HuCCT1) :
5-FU (1.0 μM) did not suppress the cell viability, but 5-FU (2.5 μM) suppressed by 23%.
VPA (0.5 mM) did not suppress the cell viability, while VPA (1.0 mM) weakly decreased it
by 11%. Combination of 5-FU (1.0 μM) and VPA (0.5 mM) markedly reduced the cell viability
by 30%. Conclusion : VPA augmented the anti-tumor effects of 5-FU in cancer cell
lines. Therefore, a combination therapy of 5-FU plus VPA may be a promising therapeutic
option for patients with pancreas cancer and cholangiocarcinoma.
ISSN
13431420
cat書誌ID
AA11166929
掲載誌名
The journal of medical investigation : JMI
58
1-2
開始ページ
106
終了ページ
109
並び順
106
発行日
2011-02
備考
The journal of medical investigation : http://medical.med.tokushima-u.ac.jp/jmi/index.html
EDB ID
251417
フルテキストファイル
言語
eng
部局
病院
医学系